ATE218880T1 - Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum - Google Patents

Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum

Info

Publication number
ATE218880T1
ATE218880T1 AT94931793T AT94931793T ATE218880T1 AT E218880 T1 ATE218880 T1 AT E218880T1 AT 94931793 T AT94931793 T AT 94931793T AT 94931793 T AT94931793 T AT 94931793T AT E218880 T1 ATE218880 T1 AT E218880T1
Authority
AT
Austria
Prior art keywords
antibiotic
bacteria
bpi
protein product
administration
Prior art date
Application number
AT94931793T
Other languages
English (en)
Inventor
Jonathan Cohen
Ada H C Kung
Lewis H Lambert Jr
Roger G Ii Little
Original Assignee
Xoma Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xoma Technology Ltd filed Critical Xoma Technology Ltd
Application granted granted Critical
Publication of ATE218880T1 publication Critical patent/ATE218880T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4742—Bactericidal/Permeability-increasing protein [BPI]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cash Registers Or Receiving Machines (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
AT94931793T 1993-09-22 1994-09-22 Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum ATE218880T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12565193A 1993-09-22 1993-09-22
US27340194A 1994-07-11 1994-07-11
PCT/US1994/011225 WO1995008344A1 (en) 1993-09-22 1994-09-22 Method of treating gram-negative bacterial infection by administration of bactericidal/permeability-increasing (bpi) protein product and antibiotic

Publications (1)

Publication Number Publication Date
ATE218880T1 true ATE218880T1 (de) 2002-06-15

Family

ID=26823793

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94931793T ATE218880T1 (de) 1993-09-22 1994-09-22 Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum

Country Status (12)

Country Link
US (2) US5523288A (de)
EP (1) EP0759774B1 (de)
JP (1) JPH09502987A (de)
AT (1) ATE218880T1 (de)
AU (1) AU695814B2 (de)
CA (1) CA2172245C (de)
DE (1) DE69430823T2 (de)
DK (1) DK0759774T3 (de)
ES (1) ES2178656T3 (de)
NZ (1) NZ275205A (de)
PT (1) PT759774E (de)
WO (1) WO1995008344A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652332A (en) * 1993-03-12 1997-07-29 Xoma Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
US5858974A (en) * 1995-07-20 1999-01-12 Xoma Corporation Anti-fungal peptides
DE69430823T2 (de) * 1993-09-22 2003-02-20 Xoma Technology Ltd., Berkeley Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum
US5447913A (en) 1994-03-11 1995-09-05 Xoma Corporation Therapeutic uses of bactericidal/permeability-increasing protein dimer products
AUPN771596A0 (en) * 1996-01-25 1996-02-15 Mclean, Allan Joseph Methods of and compositions for potentiating the action of agents active on cell-wall sites of susceptible bacteria
US5741779A (en) 1996-05-10 1998-04-21 Xoma Corporation Antithrombotic materials and methods
JP2000510845A (ja) * 1996-05-10 2000-08-22 ゾーマ コーポレイション ヒト髄膜炎菌血症のためのｂｐｉタンパク質産物の治療用途
JP2000511190A (ja) * 1996-05-23 2000-08-29 ゾーマ コーポレイション 外傷に起因する出血に見舞われたヒトにおけるｂｐｉタンパク質産物の治療用途
US5888973A (en) 1996-08-09 1999-03-30 Xoma Corporation Anti-chlamydial uses of BPI protein products
US6180604B1 (en) 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6482796B2 (en) 1996-11-01 2002-11-19 Xoma Corporation Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients
US6406880B1 (en) 1997-05-02 2002-06-18 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US7067500B2 (en) * 1997-05-02 2006-06-27 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
WO1998050576A1 (en) * 1997-05-02 1998-11-12 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
US6093573A (en) * 1997-06-20 2000-07-25 Xoma Three-dimensional structure of bactericidal/permeability-increasing protein (BPI)
WO1999052357A1 (en) * 1998-04-14 1999-10-21 Ribogene, Inc. Assays for inhibitors of bacterial translation initiation factor 3
US6013631A (en) * 1998-06-19 2000-01-11 Xoma Corporation Bactericidal/permeability-increasing protein (BPI) deletion analogs
US5977091A (en) * 1998-09-21 1999-11-02 The Research Foundation Of State University Of New York Method of preventing acute lung injury
US6790661B1 (en) * 1999-07-16 2004-09-14 Verax Biomedical, Inc. System for detecting bacteria in blood, blood products, and fluids of tissues
US6696239B1 (en) * 2000-04-20 2004-02-24 Biolog, Inc. Comparative phenotype analysis for assessment of biological active compounds such as antimicrobials
JP2004517865A (ja) * 2000-12-01 2004-06-17 ゾーマ テクノロジー リミテッド Ｂｐｉタンパク質産物またはｂｐｉインヒビターを使用する、周皮細胞増殖の調節
BR0116216A (pt) 2000-12-15 2004-08-17 Vertex Pharma Inibidores de girase e seus usos
US6835536B2 (en) 2001-08-21 2004-12-28 Micrologix Biotech Inc. Antimicrobial cationic peptides and formulations thereof
WO2003018619A2 (en) 2001-08-24 2003-03-06 Micrologix Biotech Inc. Antimicrobial and anti-inflammatory peptides
US20030232401A1 (en) * 2002-06-12 2003-12-18 Pugia Michael J. Bacterial test method by glycated label binding
US20040037895A1 (en) * 2002-08-23 2004-02-26 Alex Zhu Methods of treating involuntary facial spasms and facial wrinkles
US7655646B2 (en) * 2003-01-21 2010-02-02 Thallion Pharmaceuticals, Inc. Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
NZ561169A (en) * 2003-01-21 2008-06-30 Thallion Pharmaceuticals Inc Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals
US7300921B2 (en) * 2003-09-11 2007-11-27 Ecopia Biosciences, Inc. Polyene polyketides and methods of production
US20060106028A1 (en) * 2004-11-08 2006-05-18 Ecopia Biosciences, Inc. Polycyclic aromatics and derivatives thereof and processes for their preparation
EP1741440A1 (de) * 2005-07-08 2007-01-10 Mellitus S.L. Verwendung von BPI-proteine zur Behandlung von stoffwechselbedingten Erkrankungen und Herzkreislaufstörungen
US20080114054A1 (en) * 2006-11-14 2008-05-15 Rath Microbes Compositions and methods for reducing antimicrobial resistance of microbes
EP2601194B1 (de) 2010-08-03 2016-05-25 Merck Sharp & Dohme Corp. Als antimikrobielle wirkstoffe geeignete fusionierte imidazoylverbindungen
TWI546298B (zh) 2011-01-14 2016-08-21 維泰克斯製藥公司 旋轉酶及拓樸異構酶ｉｖ抑制劑
WO2012112438A2 (en) * 2011-02-16 2012-08-23 The Penn State Research Foundation Anti-microbial agents and compositions and methods of production and use thereof
EP2721026B1 (de) 2011-06-20 2016-03-02 Vertex Pharmaceuticals Incorporated Phosphatester von gyrase und topoisomeraseinhibitoren
US9018216B2 (en) 2012-07-18 2015-04-28 Vertex Pharmaceuticals Incorporated Solid forms of (R)-2-(5-(2-(3-ethylureido)-6-fluoro-7-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-5-yl)pyrimidin-2-yl)propan-2-yl dihydrogen phosphate and salts thereof
US20150150995A1 (en) * 2012-08-09 2015-06-04 Pono Corporation Conjugated anti-microbial compounds and conjugated anti-cancer compounds and uses thereof
WO2014160814A1 (en) * 2013-03-26 2014-10-02 Rutgers, The State University Of New Jersey Synthetic and enhanced bacterial killing involving bicyclomycin
KR101811437B1 (ko) * 2015-09-17 2018-01-25 서울대학교산학협력단 그람 음성균에 대한 항균 활성을 나타내는 끊어진 또는 꺾어진 나선 펩타이드 또는 펩타이드 유사체 및 이의 용도
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
WO2019018594A1 (en) * 2017-07-19 2019-01-24 The University Of North Carolina At Chapel Hill POTENTIATION OF THE ANTIBIOTIC EFFECT

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5028251A (de) * 1973-07-12 1975-03-22
JPS55134471A (en) * 1979-04-04 1980-10-20 Toshiba Corp Sales management system in small-scale computer constitution
CA1237671A (en) * 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
JPS60128596A (ja) * 1983-12-15 1985-07-09 東芝テック株式会社 電子キヤツシユレジスタ
JPS619790A (ja) * 1984-06-25 1986-01-17 オムロン株式会社 電子式キヤツシユレジスタ
US4863727A (en) * 1986-04-09 1989-09-05 Cetus Corporation Combination therapy using interleukin-2 and tumor necrosis factor
EP1659132A1 (de) * 1987-08-11 2006-05-24 New York University BPI Fragmente
US5198541A (en) * 1987-08-11 1993-03-30 New York University Dna encoding bactericidal/permeability-increasing proteins
WO1989012644A1 (en) * 1988-06-23 1989-12-28 Associates Of Cape Cod, Inc. Endotoxin binding protein and uses thereof
US5089274A (en) * 1989-02-14 1992-02-18 Incyte Pharmaceuticals, Inc. Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders
US5171739A (en) * 1989-02-14 1992-12-15 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and preventation thereof using a BPI protein
US5234912A (en) * 1989-02-14 1993-08-10 Incyte Pharmaceuticals, Inc. Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof
US5308834A (en) * 1989-02-14 1994-05-03 Incyte Pharmaceuticals, Inc. Treatment of endotoxin-associated shock and prevention thereof using a BPI protein
US5334584A (en) * 1989-02-14 1994-08-02 Incyte Pharamaceuticals, Inc. Recombinant, non-glycosylated bpi protein and uses thereof
AU9127591A (en) * 1990-12-03 1992-06-25 New York University Biologically active bactericidal/permeability-increasing protein fragments
US5156665A (en) * 1991-01-03 1992-10-20 Rohm And Haas Company Antimicrobial compositions comprising iodopropargyl compounds and isothiazolones and methods of controlling microbes
JPH07502642A (ja) * 1991-09-26 1995-03-23 インサイト　ファーマシューティカルズ，インコーポレイテッド 新規な形態のリポ糖結合性タンパク質（ｌｂｐ）
ATE178652T1 (de) * 1992-05-19 1999-04-15 Xoma Corp Verbessertes verfahren zur herstellung von endotoxinbindungsproteinen
WO1993023434A2 (en) * 1992-05-19 1993-11-25 Xoma Corporation Bpi-immunoglobulin fusion proteins
US5420019A (en) * 1993-02-02 1995-05-30 Xoma Corporation Stable bactericidal/permeability-increasing protein muteins
JP3946246B2 (ja) * 1993-02-02 2007-07-18 ゾーマ・コーポレイション 殺菌性／浸透性増大タンパク質（Ｂａｃｔｅｒｉｃｉｄａｌ／Ｐｅｒｍｅａｂｉｌｉｔｙ Ｉｎｃｒｅａｓｉｎｇ ｐｒｏｔｅｉｎ：ＢＰＩ）及び界面活性剤を含有する医薬組成物
MX9401807A (es) * 1993-03-12 1995-01-31 Xoma Corp Usos terapeuticos de productos de proteina que incrementan lapermeabilidad/bactericidas.
US5348942A (en) * 1993-03-12 1994-09-20 Xoma Corporation Therapeutic uses of bactericidal/permeability increasing protein products
EP0690721B1 (de) * 1993-03-12 1998-05-13 Xoma Corporation Behandlung von mycobakteriellen erkrankungen durch verabreichung von bakrerientötende, durchlässigkeitserhöhende proteinfragmente
AU694108B2 (en) * 1993-03-12 1998-07-16 Xoma Corporation Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and uses thereof
DE69430823T2 (de) * 1993-09-22 2003-02-20 Xoma Technology Ltd., Berkeley Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum

Also Published As

Publication number Publication date
CA2172245C (en) 2003-04-08
HK1014155A1 (en) 1999-09-24
PT759774E (pt) 2002-11-29
EP0759774B1 (de) 2002-06-12
AU695814B2 (en) 1998-08-20
NZ275205A (en) 1998-03-25
US6140306A (en) 2000-10-31
AU8074094A (en) 1995-04-10
CA2172245A1 (en) 1995-03-30
US5523288A (en) 1996-06-04
DE69430823T2 (de) 2003-02-20
ES2178656T3 (es) 2003-01-01
DK0759774T3 (da) 2002-10-07
DE69430823D1 (de) 2002-07-18
WO1995008344A1 (en) 1995-03-30
EP0759774A1 (de) 1997-03-05
JPH09502987A (ja) 1997-03-25

Similar Documents

Publication Publication Date Title
ATE218880T1 (de) Verfahren zur behandlung von gram-negativen bakterien infektion durch verabreichung von bakterientötendem/durchlässigkeiterhöhendem (bpi) proteinprodukt und antibiotikum
DE69527195D1 (de) Anti gram positive bakterielle verfahren und mittel
DE69636228D1 (de) Therapeutische Zusammensetzungen zur Behandlung von Lawsonia intracellularis Infektionen
ATE109624T1 (de) Bakteriocine enthaltende zusammensetzungen zur verwendung als verbesserte breitspektrum- bakterizide und verfahren zur verhütung und behandlung von mikrobiellen infektionen.
DE60325945D1 (de) Zusammensetzungen und verfahren für die behandlung von mikroorganismen-infektionen
CA2340304A1 (en) Multicomponent vaccines
GEP19991538B (en) Derivatives of Erytromycin and Pharmaceutical Composition on their Basis
BR9710768A (pt) Composto composi-Æo e processos para tratamento de infec-{es bacterianas em um mamifero hospedeiro com necessidade de tal tratamento e para prepara-Æo de 6-0-metileritromicina forma i
DE60041753D1 (de) Arzneimittel zur behandlung von c. pneumoniae infektionen
DE69839702D1 (de) Neue antimikrobielle polypeptide und verfahren für ihre verwendung.
DE69631381D1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
Walters et al. Antibiotic-induced Porphyromonas gingivalis LPS release and inhibition of LPS-stimulated cytokines by antimicrobial peptides
EP0579488B1 (de) Zusammensetzung zur Behandlung von Mastitis und Metritis
ATE182470T1 (de) Multimeres alpha-lactalbumin enthaltende antibakterielle zusammensetzung
Gadberry et al. Pasteurella pneumotropica isolated from bone and joint infections
EP0966196A4 (de) Zusammensetzung zur organ-kryokonservierung und behandlung von viralen und bakteriellen infektionen
WO2005021575A3 (en) Bacterial signaling molecules that down-regulate pathogenic bacterial virulence properties
CY1107038T1 (el) Μεθοδος θεραπειας βακτηριακων λοιμωξεων με χρηση της γεμιφλοξασινης ή ενος αλατος αυτης και ενος αντιβιοτικου β-λακταμης
HUP0401586A2 (hu) Baktériumellenes szer
ATE201995T1 (de) Verfahren zur prävention und behandlung der rindermastitis
FR2696179B1 (fr) Derives de thioalkylthiocarbacephalosporine, procede pour leurs preparations et formulation pharmaceutique les contenant pour le traitement ou la prophylaxie des infections bacteriennes.
DE60228324D1 (de) Verfahren zur behandlung von bakteriellen infektionen mit gemifloxacin oder einem seiner salze und einem antibakteriellen carbapenem-mittel
Sadick et al. The intrinsic antimicrobial activity of selected sclerosing agents in sclerotherapy
EP1021445A4 (de) Antibakterielle carbapenem-verbindungen, zubereitungen die solche verbindungen enthalten und behandlungsverfahren
Bustamante Initial empiric therapy for fever in neutropenia

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee